Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

LexaGene announces improved bacterial and drug resistance test panel for veterinarian care

LexaGene announces improved bacterial and drug resistance test panel for veterinarian care

LexaGene Holdings (CVE: LXG – OTCQB: LXXGF) CEO Dr. Jack Regan joined Steve Darling from Proactive to share news the company has announced the release of a news test panel within the MiQLab testing unit.

Regan telling Proactive, the next-generation test panel will screen for 10 pathogens and 30 gene variants. The new panel is expected to detect 96% of bacterial UTIs & 93% of bacterial SSTI’s and pick up a much higher percentage of genes that confer resistance to some of the most commonly prescribed antibiotics.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK